$INO News

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile

Inovio Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Precigen: Full Commercial Validation And Room To Run

Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms

Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript

Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call

Inovio Pharmaceuticals, Inc. (INO) Presents at World Federation of Hemophilia World Congress - Slideshow

What's Going On With Inovio Pharmaceuticals Stock On Tuesday?

Inovio Pharmaceuticals shares are trading lower after the company priced a $17.5 million public offering.

Inovio Pharmaceuticals shares are trading lower after the company priced a $17.5 million public offering.

What's Behind The Drop In Inovio Pharmaceuticals Stock Today?

INOVIO Pharmaceuticals Prices ~$17.5M Offering Of 12.5M Shares Of Common Stock And Warrants To Purchase Up To 12.5M Shares Of Common Stock, At A Combined Purchase Price Of $1.40

Reported Earlier, INOVIO Pharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock, Series A And Series B Warrants

Inovio Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation

Inovio Stock Up On Earnings, Pipeline Progress

Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript

INOVIO Pharmaceuticals Estimates Its Current Cash, Cash Equivalents And Short-Term Investments Balances To Support The Company's Operations Into Q4 2026; Projection Includes An Operational Net Cash Burn Estimate Of ~$22M For Q1 2026.

Inovio Pharmaceuticals Q4 EPS $(0.26) Beats $(0.38) Estimate

Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript